Fungal polyketides display remarkable structural diversity and bioactivity, and 31 therefore the biosynthesis and engineering of this large class of molecules is 32 therapeutically significant. Here, we successfully recoded, constructed and 33 characterized the biosynthetic pathway of the formation of bikaverin, a tetracyclic 34 polyketide with antibiotic, antifungal and anticancer properties, in S. cerevisiae. We 35 used a green fluorescent protein (GFP) tagging strategy to identify the low expression 36 of Bik1 (polyketide synthase) as the bottleneck step in the pathway, and a promoter 37 exchange strategy to increase expression of Bik1 and bikaverin yield. To further 38 increase product yield, we used an enzyme-fusion strategy to couple the 39 monooxygenase (Bik2) and methyltransferase (Bik3) to efficiently channel 40 intermediates between modifying enzymes, leading to a dramatic improvement of 41
with two oxidations catalyzed by the FAD-dependent monooxygenase Bik2, and two 84 methylations catalyzed by O-methyltransferase Bik3, to form the final product 85 bikaverin ( Fig. 1a ). 86
In this study, we successfully recoded, constructed and characterized the 87 biosynthetic pathway of the complex polyketide bikaverin in S. cerevisiae. We 88 developed a GFP-tagging method for identifying the expression of bik1 as the 89 bottleneck in the pathway and used a promoter exchange strategy to increase 90 expression of bik1 and subsequently, bikaverin yield. In addition, we verified the 91 genes essential for bikaverin synthesis and characterized the biosynthetic pathway 92 through a bottom-up strategy. Finally, we optimized bikaverin production by 93 developing an enzyme-fusion method to couple the modifying enzymes Bik2 and 94
Bik3, allowing channeling of intermediates between the enzymes and achieving a 95 ~60-fold increase in the final yield of the molecule. The three strategies we describe 96 expand the toolbox of polyketide biosynthesis in S. cerevisiae, and will enable 97 development of yeast as a host for the biosynthetic engineering of fungal polyketides 98 and other desired molecules. 99 (accession numbers: Bik1, S0DZM7; Bik2, S0E2X6; Bik3, S0E608; Bik6, S0DZN4) 109 from 201322. Most of the protein sequences were identical in the two versions, 110 excepting a few single amino acid variants and gaps ( Supplementary Fig. 1 ). We 111 synthesized S. cerevisiae-optimized bik1, bik2, bik3 and bik6 genes from both 112 versions (V1-2007 and V2-2013) under the control of the yeast endogenous 113 promoters, PRPS2, PTEF1, PTPI1 and PPGK1, respectively ( Fig. 1b ). In addition, to 114 facilitate the post-translational activation of the PKS, we chose two PPTase's to 115 activate Bik1: Ppt1, the native PPTase from F. fujikuroi, and NpgA, a PPTase from A. 116 nidulans, which previously has been used successfully in yeast for activating PKSs 117 and nonribosomal peptide synthetases (NPRSs)6,12,13. Both enzyme coding genes were 118 added into the constructed yeast bikaverin expression cassette under the control of the 119 ENO2 and TEF promoter, respectively. The resulting bikaverin expression cassette 120 was transformed into yeast, as strain yZM001 for V1-2007 and yZM006 for V2-2013. 121 The strains failed to turn red, suggesting that the red-colored compound bikaverin was 122 not being produced. 123
To probe the bikaverin pathway for bottlenecks limiting biosynthesis, we 124 developed a GFP-fusion strategy to confirm that all genes were well expressed and 125 translated into proteins efficiently. The coding sequence for green fluorescent protein 126 (GFP) was fused, in frame, to the 3' end of the individual genes. When the genes bik2, To confirm that bikaverin biosynthesis was due to higher expression of bik1 140 and not because of the use of galactose instead of glucose as the carbon source, we 141 introduced a galactose-independent system to regulate the GAL1 promoter. We 142 expressed a GAL4(1-93).ER.VP16(GEV) plasmid to produce a tribrid protein 143 comprising a GAL4 DNA binding domain, an estrogen receptor and a VP16 144 domain23. When bound to β-estradiol, this complex translocate into the nucleus and 145 binds to PGAL1 sequences to activate gene transcription; consequently, an increase in 146 β-estradiol availability leads to higher rates of transcription23. With bik1 under the 147 control of this system, increasing the concentration of β-estradiol in the medium led to 148 deeper red colony color ( Fig. 2e ), indicating higher yields of bikaverin and confirming 149 that the higher expression of bik1 indeed resulted from the promoter exchange 150 strategy. 151
We also observed that the V1-2007 strain yZM002 did not turn red using the 152 same promoters as used in yZM009, and no bikaverin was produced. We further 153 checked the function of each V1-2007 enzyme in yeast by replacing them with their 154 counter part from the V2, and found all three V1 proteins were expressed much less 155 efficiently ( Supplementary Fig. 3 ). As a result, V2-2013 clusters were used for further 156 characterization. In the strain containing only bik1 and bik3 (yZM028), two small peaks of m/z 185 339.09 (3) and 339.08 (4) were detected ( Supplementary Fig. 7 ). HPLC-MS retention strain yZM009 containing the entire pathway, suggesting that pre-bikaverin can be 191 methylated by Bik3 but that this is unfavored relative to oxo-pre-bikaverin and other 192 downstream substrates including C3/C8 me-oxo-pre-bikaverin and nor-bikaverin . 193
In strain yZM009 containing all the pathway genes, two peaks of m/z 353.05 194 were detected ( Supplementary Fig. 8c ). These were postulated to be the two mono-195 methylated forms of oxo-pre-bikaverin: C3-me-oxo-pre-bikaverin (6) and C8-me-196 oxo-pre-bikaverin (5). In addition, a peak of dehydroxy-bikaverin (m/z 367.07) (7), 197 the di-methylated form of oxo-pre-bikaverin, was detected in this strain 198 ( Supplementary Fig. 8d ), suggesting that Bik3 is able to methylate oxo-pre-bikaverin 199 twice in yeast. Nor-bikaverin (8) However, at m/z 369.05, only one peak was detected, which suggested that C8-me-203 oxo-pre-bikaverin, not C3-me-oxo-pre-bikaverin, was the favored substrate of bik2, 204 although it is possible that the oxidized form of C3-me-oxo-pre-bikaverin cannot be 205 isolated using the HPLC-MS conditions tested ( Supplementary Fig. 8e ). With this 206 certain preference for substrates, Bik2 only catalyzes the oxidation C8-me-oxo-pre-207 bikaverin, while Bik3 can methylate both C3-and C8-me-oxo-pre-bikaverin. The 208 final product, bikaverin (m/z 383.06) (9), was only detected in the strain containing 209 the complete pathway, confirming that Bik1, Bik2 and Bik3 are all essential and 210 sufficient for the de novo biosynthesis of bikaverin ( Supplementary Fig. 8f ). 211
Using the results from the HPLC-MS experiments, we traced out the putative 212 bikaverin biosynthetic pathway in yeast ( Fig. 3c ). Pre-bikaverin is first oxidized to 213 oxo-pre-bikaverin by Bik2, then to dehydroxy-bikaverin by two methylation steps 214 catalyzed by Bik3. Dehydroxy-bikaverin can then be oxidized to be form the final 215
Pathway optimization to increase Bikaverin production 219
To further optimize the yield of bikaverin, we applied the promoter exchange 220 strategy to the modifying enzymes in the bikaverin pathway. The GFP-fusion strategy 221 revealed that the expression of Bik2 and Bik3 was significantly lower than the 222 expression of Bik1 following the use of the GAL1 promoter ( Supplementary Fig. 9 ). 223
Changing the promoter of bik2 and bik3 to PGAL1 resulted in a 3-fold increase in 224 bikaverin yield from ~0.74mg/L to ~2.9mg/L for bik2 and an increase to ~1.37mg/L 225 for bik3 ( Fig. 4a ). Further, changing the promoter of both bik2 and bik3 to PGAL1 226 resulted in a bikaverin yield of ~3.65mg/L, which was five-fold higher than the 227 original strain yZM009. 228
Characterization of the bikaverin biosynthetic pathway highlighted that pre-229 bikaverin is modified in a stepwise manner by the monooxygenase Bik2 and then the 230 O-methyltransferase Bik3. This process results in many intermediates, some of which 231 are dead-end products. This led us to hypothesize that channeling the mono-232 oxygenated pre-bikaverin from Bik2 to Bik3 may increase the yield of bikaverin. 233
Guided by homology modeling of the two enzymes, which revealed that the active 234 pocket and FAD binding site of Bik2 are near its N-terminal and the SAM binding 235 site and active pocket of Bik3 are close to C-terminal ( Supplementary Fig. 10 ), we 236 fused Bik2 and Bik3 together using a (GGGS)3 linker to bring the N-terminal of Bik2 237 and the C-terminal of Bik3 in close proximity25. The resulting strain pZM-y037 238 displayed a significant increase in the yield of bikaverin to ~41 mg/L, approximately 239 11-fold higher than the strain with PGAL1 driving bik1, bik2 and bik3 (yZM031), and 240 nearly 60-fold higher than the original strain producing bikaverin (yZM009) (Fig. 4a,  241 b). The protein level of the Bik2-Bik3 fusion protein was not higher than the levels 242 detected of Bik2 or Bik3 respectively when expressed as individual genes 243 ( Supplementary Fig. 11 ), indicating that the fusion protein In this study, we demonstrated the efficient biosynthesis of the complex fungal 253 polyketide bikaverin in the heterologous host S. cerevisiae. To achieve this, we 254 reconstructed the bikaverin pathway in yeast by recoding and synthesizing the genes 255 bik1, bik2, bik3, and bik6 from F. fujikoroi along with two PPTases that activate the 256 ACP domain of the PKS Bik1. 257
To optimize production of bikaverin, we used three strategies to debug the 258 biosynthetic pathway and increase the finale yield, and these can be extrapolated to 259 the production of other small molecules in yeast. We used a GFP-fusion strategy to 260 quickly identify low Bik1 expression as the initial bottleneck step in the bikaverin 261 biosynthetic pathway (Fig. 5a ). We used a promoter exchange strategy to increase 262 expression of Bik1, and subsequently increase bikaverin yield (Fig. 5b ). This strategy 263 was also used to increase expression of the modifying enzymes Bik2 and Bik3, further 264 increasing the yield of the final product. In addition, we used an enzyme-fusion 265 strategy to fuse together the modifying enzymes Bik2 and Bik3 to efficiently channel 266 intermediates through the pathway, leading to an 11-fold increase in bikaverin yield 267 ( Fig. 5c ). We postulate that this fusion may help to channel substrates from one 268 modifying enzyme to the other, preventing the diffusion of intermediates and 269 improving the efficiency of substrate transfer between the two enzymes. In many 270 biosynthetic pathways, modifications such as the methylation, glycosylation and 271 hydroxylation occur step-wise26-29; this protein fusion strategy might similarly be 272 applied to such pathways for improving yield. 273
Previously, bikaverin was biosynthesized in its native host F. fujikoroi18. 274
Yeast is a significantly better model organism for the biosynthetic engineering of 275 fungal polyketides, with many available synthetic biological tools including pathway 276 assembly, CRISPR genome editing and even whole chromosome synthesis and 11 characterize the bikaverin biosynthetic pathway using top-down and bottom-up 279 strategies. Our result showed that genes bik1, bik2 and bik3 are essential for the 280 production of bikaverin, while omitting of the permease encoding gene bik6 had 281 minimal effect in yeast. We were also able to confirm the production of the proposed 282 intermediates of the bikaverin biosynthetic pathway and determine the order of the 283 modification steps catalyzed by Bik2 and Bik3. In addition, the use of yeast promoters 284 and terminators to drive expression of the bikavarin pathway genes led us to establish 285 expression that was not dependent on the transcription regulation systems present in 286 F. fujikuroi. Consequently, our strains display stable, tunable and scalable bikaverin 287 production that is not dependent on environmental conditions. This is an added 288 advantage of using yeast as a host for the bioengineering of polyketides. 289
The approach described in this study greatly expands the toolbox for 290 biosynthetic engineering of fungal polyketide pathways in yeast. Moreover, in the 291 polyketides biosynthesis, the type I iterative PKS enzyme works as an assembly line 292 with each domain catalyzing a different function and this predictability of function 293 implied that PKSs can be rationally engineered5,37. It has been reported that swapping 294 of domains between PKSs results in new diverse functions in vitro38-40. The present 295 results now allow for the implementation of similar combinatory hybrid PKS 296 experiments in S. cerevisiae with the aim of create novel PKS enzymes that generate 297 new polyketides. We hope that our study including the tools described in this study, as 298 well as the suite of pre-existing synthetic biology tools, will promote biosynthetic 299 engineering of PKSs in S. cerevisiae, allowing for the exploration of the chemical 300 space of polyketides and the development of novel therapeutics with diverse 301
bioactivities. 302
Yeast strains were cultured in 5 ml of SC-Ura liquid medium at 30°C, 250 rpm, 343 overnight to saturation. Cells were harvested by centrifugation at 5000 rpm for 5 min, 344 followed by 3x 2 ml washes with water, and then inoculated to an initial OD600 of 0.5 345 in 30 ml of SC-Ura liquid medium with either glucose or galactose as the carbon 346 source. Cultures were incubated at 30°C, 250 rpm, for 96 hours. Appropriate volumes 347 of cell cultures (5-2 ml) were centrifuged for 10 min at 12000 rpm. Cell pellets were 348 resuspended with 0.5 ml water in a 2 mL tube, and 200 uL of acid-washed glass beads 349 (Sigma, G8772-100G) were added into the tubes along with 0.5 mL ethyl acetate. 350
Resulting suspensions were vortexed for 20 min and centrifuged for 10 min at 12,000 351 rpm before the supernatant was transferred to a new tube; this was repeated 5 times. Boxed intermediates were only detected in the absence of bik2 ( Supplementary Fig.  443 6). 444 445 Fig. 4 Optimization of bikaverin yield using promoter exchange and enzyme fusion 446 strategies. a Driving bik2 and bik3 using GAL1 lead to modest increases in bikaverin 447 yield. Fusing bik2 and bik3 led to a dramatic increase in bikaverin production, 60-fold 448 higher than the original strain. b The bikaverin pathway construct containing bik2 and 449 bik3 fused to form the bik2,3 fusion gene. The whole pathway was assembled into a 450 plasmid vector with URA3. 451 Bik2-Bik3 
